Literature DB >> 12663847

The impact of weight gain on quality of life among persons with schizophrenia.

David B Allison1, Joan A Mackell, Diana D McDonnell.   

Abstract

Weight gain has been associated with the use of antipsychotic medications, and research has linked obesity with reduced quality of life. This study sought to assess the impact of weight gain on persons with schizophrenia who are taking antipsychotic medications. The Psychological Well-Being Index, a measure of quality of life, was distributed to individuals with schizophrenia who belonged to mental health associations. Among 286 respondents, 56 percent gained no weight over a six-month period while taking antipsychotic medications, 19 percent gained one to ten pounds, 12 percent gained 11 to 20 pounds, and 14 percent gained more than 20 pounds. When gender and use of antipsychotics were controlled for, weight gain was related to poorer quality of life and reduced well-being and vitality. Clinicians should consider the effect of weight gain on quality of life when prescribing antipsychotics and should help patients adopt weight maintenance behaviors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663847     DOI: 10.1176/appi.ps.54.4.565

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  52 in total

Review 1.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

Review 2.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

3.  Dietary intake of patients with schizophrenia.

Authors:  Martin Strassnig; Jaspreet Singh Brar; Rohan Ganguli
Journal:  Psychiatry (Edgmont)       Date:  2005-02

Review 4.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 5.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

6.  Performance of a weight-related measure of Quality of Life in a psychiatric sample.

Authors:  Ronette L Kolotkin; Ross D Crosby; Patricia K Corey-Lisle; Hong Li; Jodi M Swanson
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

7.  Effects of social networks on physical health among people with serious mental illness.

Authors:  Sungkyu Lee; Yin-Ling Irene Wong; Aileen Rothbard
Journal:  Psychiatr Q       Date:  2014-12

8.  Exercise capacity and quality of life in patients with schizophrenia.

Authors:  Arno Kerling; Uwe Tegtbur; Marc Ziegenbein; Lena Grams; Dirk Robert Heinze; Marcel Sieberer
Journal:  Psychiatr Q       Date:  2013-12

9.  Lack of Association between Glutathione S-Transferase-M1, -T1, and -P1 Polymorphisms and Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.

Authors:  Young-Min Park; Heon-Jeong Lee; Seung-Gul Kang; Jung-Eun Choi; Jae-Hyuck Cho; Leen Kim
Journal:  Psychiatry Investig       Date:  2010-05-12       Impact factor: 2.505

10.  G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.

Authors:  Young-Min Park; Young-Cho Chung; Seung-Hwan Lee; Kang-Joon Lee; Hyun Kim; Jung-Eun Choi; Seung-Gul Kang; Min-Soo Lee; Leen Kim; Heon-Jeong Lee
Journal:  Psychiatry Investig       Date:  2009-03-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.